Literature DB >> 18395582

Premenstrual syndrome.

Kimberly Ann Yonkers1, P M Shaughn O'Brien, Elias Eriksson.   

Abstract

Most women of reproductive age have some physical discomfort or dysphoria in the weeks before menstruation. Symptoms are often mild, but can be severe enough to substantially affect daily activities. About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also meet criteria for premenstrual dysphoric disorder (PMDD). Mood and behavioural symptoms, including irritability, tension, depressed mood, tearfulness, and mood swings, are the most distressing, but somatic complaints, such as breast tenderness and bloating, can also be problematic. We outline theories for the underlying causes of severe PMS, and describe two main methods of treating it: one targeting the hypothalamus-pituitary-ovary axis, and the other targeting brain serotonergic synapses. Fluctuations in gonadal hormone levels trigger the symptoms, and thus interventions that abolish ovarian cyclicity, including long-acting analogues of gonadotropin-releasing hormone (GnRH) or oestradiol (administered as patches or implants), effectively reduce the symptoms, as can some oral contraceptives. The effectiveness of serotonin reuptake inhibitors, taken throughout the cycle or during luteal phases only, is also well established.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395582      PMCID: PMC3118460          DOI: 10.1016/S0140-6736(08)60527-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  166 in total

1.  Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review.

Authors:  K Wyatt; P Dimmock; P Jones; M Obhrai; S O'Brien
Journal:  BMJ       Date:  2001-10-06

2.  The premenstrual syndrome.

Authors:  R GREENE; K DALTON
Journal:  Br Med J       Date:  1953-05-09

3.  The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors.

Authors:  S Ramcharan; E J Love; G H Fick; A Goldfien
Journal:  J Clin Epidemiol       Date:  1992-04       Impact factor: 6.437

4.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.

Authors:  K S Kendler; L M Karkowski; L A Corey; M C Neale
Journal:  Am J Psychiatry       Date:  1998-09       Impact factor: 18.112

5.  Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.

Authors:  R Schellenberg
Journal:  BMJ       Date:  2001-01-20

6.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  Lack of effect of induced menses on symptoms in women with premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; G N Grover; K L Muller; G R Merriam; D R Rubinow
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

8.  Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria.

Authors:  J Melke; L Westberg; M Landén; C Sundblad; O Eriksson; F Baghei; R Rosmond; E Eriksson; A Ekman
Journal:  Psychoneuroendocrinology       Date:  2003-04       Impact factor: 4.905

9.  How does premenstrual dysphoric disorder relate to depression and anxiety disorders?

Authors:  Mikael Landén; Elias Eriksson
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

10.  Severity of premenstrual symptoms in a health maintenance organization population.

Authors:  Barbara Sternfeld; Ralph Swindle; Anita Chawla; Stacey Long; Sean Kennedy
Journal:  Obstet Gynecol       Date:  2002-06       Impact factor: 7.661

View more
  111 in total

1.  Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation.

Authors:  J L Spencer-Segal; M C Tsuda; L Mattei; E M Waters; R D Romeo; T A Milner; B S McEwen; S Ogawa
Journal:  Neuroscience       Date:  2011-11-23       Impact factor: 3.590

Review 2.  Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder.

Authors:  Erika Comasco; Inger Sundström-Poromaa
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

Review 3.  [The effects of hormone replacement therapy on mind and brain].

Authors:  P Baldinger; G Kranz; A Höflich; M Savli; P Stein; R Lanzenberger; S Kasper
Journal:  Nervenarzt       Date:  2013-01       Impact factor: 1.214

4.  Studies on the physiology and alternative treatment of premenstrual syndrome.

Authors:  Athol Kent
Journal:  Rev Obstet Gynecol       Date:  2008

Review 5.  Monkeys, mice and menses: the bloody anomaly of the spiny mouse.

Authors:  Nadia Bellofiore; Jemma Evans
Journal:  J Assist Reprod Genet       Date:  2019-01-05       Impact factor: 3.412

6.  Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study.

Authors:  Elizabeth R Bertone-Johnson; Brian W Whitcomb; Stacey A Missmer; JoAnn E Manson; Susan E Hankinson; Janet W Rich-Edwards
Journal:  J Womens Health (Larchmt)       Date:  2014-08-06       Impact factor: 2.681

Review 7.  Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents.

Authors:  Andrea J Rapkin; Judith A Mikacich
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

8.  Effects of Elsholtzia splendens and Cirsium japonicum on premenstrual syndrome.

Authors:  Mi-Sook Chung; Gun-Hee Kim
Journal:  Nutr Res Pract       Date:  2010-08-31       Impact factor: 1.926

9.  The phenomenology of premenstrual syndrome in female medical students: a cross sectional study.

Authors:  Magdy Hassan Balaha; Mostafa Abd El Monem Amr; Mohammed Saleh Al Moghannum; Nouria Saab Al Muhaidab
Journal:  Pan Afr Med J       Date:  2010-04-23

Review 10.  The influence of stress at puberty on mood and learning: role of the α4βδ GABAA receptor.

Authors:  S S Smith
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.